Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

L0400000

Levodopa

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

3,4-Dihydroxy-L-phenylalanine, 3-(3,4-Dihydroxyphenyl)-L-alanine, L-3-Hydroxytyrosine, L-DOPA, Levodopa

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

20 MG
149,00 €

149,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
20 MG
149,00 €

About This Item

Formula condensata:
(HO)2C6H3CH2CH(NH2)CO2H
Numero CAS:
59-92-7
Peso molecolare:
197.19
Beilstein:
2215169
Numero MDL:
MFCD00002598
Codice UNSPSC:
41116107
ID PubChem:
329817362
NACRES:
NA.24

149,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk

Grado

pharmaceutical primary standard

Famiglia di API

levodopa

Produttore/marchio commerciale

EDQM

Punto di fusione

276-278 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O

InChI

1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
WTDRDQBEARUVNC-LURJTMIESA-N

Informazioni sul gene

human ... DRD3(1814)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Levodopa EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302,H315,H319,H335

Classi di pericolo

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

USP

USP

1361010

Levadopa Related Compound A

Levodopa Related Compound A Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2095

Levodopa Related Compound A

Carbidopa Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1655

Carbidopa

Carbidopa United States Pharmacopeia (USP) Reference Standard

USP

1095506

Carbidopa

USP

USP

1420006

Levodopa Related Compound B

Levodopa Related Compound B Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2096

Levodopa Related Compound B

Benserazide hydrochloride ≥98% (HPLC), solid

Sigma-Aldrich

B7283

Benserazide hydrochloride

Pol Nadal-Jimenez et al.
Journal of bacteriology, 196(14), 2681-2690 (2014-05-13)
The iron binding siderophore pyoverdine constitutes a major adaptive factor contributing to both virulence and survival in fluorescent pseudomonads. For decades, pyoverdine production has allowed the identification and classification of fluorescent and nonfluorescent pseudomonads. Here, we demonstrate that PvdP, a
Nicolas Morin et al.
Experimental neurology, 256, 105-116 (2013-01-31)
The treatment of motor symptoms of Parkinson disease (PD) with the dopamine (DA) precursor, l-3,4-dihydroxyphenylalanine (l-DOPA) introduced 50years ago still remains a very effective medication. However, involuntary movements termed l-DOPA-induced dyskinesias (LID) appear in the vast majority of PD patients
Elahe Molaakbari et al.
The Analyst, 139(17), 4356-4364 (2014-07-12)
A novel carbon paste electrode modified with ZnO nanorods and 5-(4'-amino-3'-hydroxy-biphenyl-4-yl)-acrylic acid (3,4'-AAZCPE) was fabricated. The electrochemical study of the modified electrode, as well as its efficiency for the electrocatalytic oxidation of levodopa, is described. The electrode was employed to
Lukas L Imbach et al.
Parkinsonism & related disorders, 20(11), 1283-1286 (2014-09-28)
Diagnosis and treatment of tremor are largely based on clinical assessment. Whereas in some patients tremor may respond to dopaminergic treatment, in general l-Dopa response to tremor varies considerably. The aim of this study was to predict l-Dopa response by
Vincent J J Odekerken et al.
Neurology, 84(13), 1355-1361 (2015-03-01)
To assess the neuropsychological outcome 12 months after bilateral deep brain stimulation (DBS) of the globus pallidus pars interna (GPi) or subthalamic nucleus (STN) for advanced Parkinson disease. We randomly assigned patients to receive either GPi DBS or STN DBS.
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.